Mohammed A Dahab

15PUBLICATIONS
32CO-AUTHORS
Molecular targetsCheminformatics and quantitative structure-activity relationshipsBiologically active moleculesBiomolecular modelling and designPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jun 22, 2026
Identification of Sulfonamide-Based Thiazolidine-2,4-Dione Derivatives as VEGFR-2 and Tumor-Associated hCA IX Inhibitors With Hypoxia-Targeted Anti-Colorectal Cancer Activity.

|Dec 24, 2024
Phthalazine Derivatives as VEGFR-2 Inhibitors: Docking, ADMET, Synthesis, Design, Anticancer Evaluations, and Apoptosis Inducers.

Hatem Hussein Bayoumi, Mohamed-Kamal Ibrahim, Mohammed A Dahab

|Aug 28, 2024
Rationale, in silico docking, ADMET profile, design, synthesis and cytotoxicity evaluations of phthalazine derivatives as VEGFR-2 inhibitors and apoptosis inducers.

Hatem Hussein Bayoumi, Mohamed-Kamal Ibrahim, Mohammed A Dahab

|Jul 09, 2024
Exploration of the VEGFR-2 inhibition activity of phthalazine derivatives: design, synthesis, cytotoxicity, ADMET, molecular docking and dynamic simulation.

Hatem Hussein Bayoumi, Mohamed-Kamal Ibrahim, Mohammed A Dahab

|Sep 21, 2023
Synthesis, biological evaluation and computer-aided discovery of new thiazolidine-2,4-dione derivatives as potential antitumor VEGFR-2 inhibitors.

Hazem Elkady, Osama A El-Dardir, Alaa Elwan

|Aug 02, 2023
Discovery of new thieno[2,3-d]pyrimidines as EGFR tyrosine kinase inhibitors for cancer treatment.

Eman A Sobh, Mohammed A Dahab, Eslam B Elkaeed

Pageof 3

Frequent Collaborators

9 joint publications

Ibrahim H Eissa

6 joint publications

Ahmed M Metwaly

5 joint publications

Hazem Elkady

4 joint publications

Eslam B Elkaeed